Przejdź do zawartości
Merck

The discovery of potent antagonists of NPBWR1 (GPR7).

Bioorganic & medicinal chemistry letters (2011-12-27)
F Anthony Romero, Nicholas B Hastings, Remond Moningka, Zhiqiang Guo, Ming Wang, Jerry Di Salvo, Ying Lei, Dorina Trusca, Qiaolin Deng, Vincent Tong, Jenna L Terebetski, Richard G Ball, Feroze Ujjainwalla
ABSTRAKT

The synthesis and evaluation of small molecule antagonists of the G protein-coupled receptor NPBWR1 (GPR7) are reported for the first time. [4-(5-Chloropyridin-2-yl)piperazin-1-yl][(1S,2S,4R)-4-{[(1R)-1-(4-methoxyphenyl)ethyl]amino}-2-(thiophen-3-yl)cyclohexyl]methanone (1) emerged as a hit from a high-throughput screen. Examination of substituents that focused on replacing the 5-chloropyridine and 4-methoxybenzylamino groups of 1 led to the identification of compounds that exhibited subnanomolar potencies as low as 660pM (9k) in the functional assay and 200pM in the binding assay (9i).

MATERIAŁY
Numer produktu
Marka
Opis produktu

Supelco
Benzylamine, for GC derivatization, LiChropur, ≥99.0%
Sigma-Aldrich
Benzylamine hydrochloride
Sigma-Aldrich
Benzylamine, purified by redistillation, ≥99.5%
Sigma-Aldrich
Benzylamine, ReagentPlus®, 99%